ZeroHarm Sciences, a nano-formulated, plant-based nutraceutical brand, has raised ₹65 crore in a funding round led by Kotak Alternate Asset Managers Limited’s Kotak Life Sciences Fund I (KLSF-I) and Alkemi Growth Capital, the company announced on Thursday.
Under the deal, Kotak Alts injected ₹40 crore through its Kotak Life Sciences Fund I, while Alkemi Growth Capital, a venture fund focused on healthcare and consumer wellness, contributed ₹25 crore to the round. Cipher-Plexus served as the exclusive financial advisor to the transaction.
The fresh capital will be deployed to build what ZeroHarm calls a “Trust over Promise” health platform — a model that aims to demonstrate supplement efficacy through measurable consumer health outcomes rather than traditional marketing claims.
The company plans to use the funds to strengthen its national brand presence, accelerate international expansion into key markets including the United States, United Kingdom and the Middle East, and scale up its vertically integrated research, development and manufacturing ecosystem.
ZeroHarm Sciences, co-founded by CEO Sachin Darbarwar, develops 100% plant-based health supplements using proprietary nano-formulation technology designed to improve bioavailability and drive real-world health benefits. According to the company, the partnership with Kotak Alts and Alkemi Growth Capital brings long-term investors aligned with its vision that the future of nutraceuticals lies in measurable outcomes rather than louder claims.
The Hyderabad-based startup operates a vertically integrated model that spans formulation science and manufacturing, and will leverage the new funding to deepen its footprint both domestically and internationally.
Also Read